Form 4: ANI Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Muthusamy Shanmugam, a Director and Officer at ANI Pharmaceuticals, sold shares of common stock over three days in March 2024 under a pre-arranged trading plan.
Summary
- Muthusamy Shanmugam, a Director and Officer at ANI Pharmaceuticals, sold shares of common stock over three days in March 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on November 27, 2023.
- On March 5, 2024, 10,093 shares were sold at a weighted average price of $65.35, with prices ranging from $64.45 to $66.58.
- On March 6, 2024, 14,822 shares were sold at a weighted average price of $65.47, with prices ranging from $64.84 to $66.04.
- On March 7, 2024, 15,085 shares were sold at a weighted average price of $66.35, with prices ranging from $65.53 to $67.00.
- Following these transactions, Shanmugam directly owns 68,652 shares.
- Shanmugam indirectly owns 842,620 shares through Esjay LLC and 5,000 shares through SS Pharma LLC.
- Shanmugam holds voting and dispositive power over the shares held by both Esjay LLC and SS Pharma LLC.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The share sales could have a minor negative impact on shareholder value due to increased selling pressure, but the impact is likely to be minimal given the pre-planned nature of the transactions.
Key Dates
| Date | Description |
|---|---|
| 2023-11-27 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-03-05 | Date of first transaction: sale of 10,093 shares |
| 2024-03-06 | Date of second transaction: sale of 14,822 shares |
| 2024-03-07 | Date of third transaction: sale of 15,085 shares |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.